FINWIRES · TerminalLIVE
FINWIRES

Williams Expected to Post Lower Q2 Results as Winter Boost Recedes, UBS Says

By

Williams (WMB) is expected to report softer Q2 results as the benefit from severe winter weather fades and seasonal weakness across several segments weighs on performance, UBS Securities said Monday in a note.

Adjusted EBITDA may drop to about $1.89 billion in Q2 from $2.25 billion in Q1 as the gas-marketing business normalizes after a strong start to the year and contributions from the Transco and West segments ease in the spring, UBS said.

Williams' full-year performance is expected to remain solid, supported by steady demand across its core pipeline and gathering operations, the note said. UBS also pointed to long-term growth potential from the company's power initiatives, including the Neo project, which is slated to begin operating in H2 2028 and may add meaningful earnings over time.

Investors are likely to focus on management's commentary around natural-gas market conditions, progress on power-innovation projects, capital spending, growth plans, LNG-related infrastructure, and the company's approach to potential mergers and acquisitions during the earnings call, the note said.

Q2 results are expected Aug. 3.

UBS has a buy rating on Williams stock with a $91 price target.

Price: $74.86, Change: $-0.20, Percent Change: -0.27%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC